PolyPid (PYPD) CEO details stock and option holdings in Form 3

Rhea-AI Filing Summary

PolyPid Ltd. director and Chief Executive Officer Dikla Czaczkes Akselbrad filed an initial ownership report listing her existing equity position in the company. The filing shows direct holdings of 934 Ordinary Shares and multiple stock options to buy additional Ordinary Shares at exercise prices ranging from 92.8900 down to 2.6700 per share, with expiration dates between 2026 and 2035. Several option grants are already fully vested, while others vest on a quarterly basis over future periods, indicating a mix of long-standing and more recent compensation awards rather than new market purchases or sales.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Akselbrad Dikla Czaczkes

(Last) (First) (Middle)

C/O POLYPID LTD.

18 HASIVIM STREET

(Street)

PETACH TIKVA 495376

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
PolyPid Ltd. [ PYPD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	934	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	07/05/2016	04/05/2026	Ordinary Shares	279(1)	$92.89	D
Stock option (right to buy)	08/25/2017	08/24/2026	Ordinary Shares	228(2)	$92.89	D
Stock option (right to buy)	03/21/2017	12/21/2026	Ordinary Shares	1,713(3)	$117.99	D
Stock option (right to buy)	08/08/2023	05/05/2033	Ordinary Shares	2,833(4)	$23.07	D
Stock option (right to buy)	10/01/2019	06/11/2030	Ordinary Shares	3,187(5)	$23.07	D
Stock option (right to buy)	08/09/2022	08/09/2032	Ordinary Shares	1,827(6)	$23.07	D
Stock option (right to buy)	07/01/2023	05/03/2032	Ordinary Shares	3,333(7)	$23.07	D
Stock option (right to buy)	08/07/2024	10/09/2033	Ordinary Shares	30,486(8)	$11.01	D
Stock option (right to buy)	08/06/2024	07/02/2034	Ordinary Shares	198,900(9)	$4.64	D
Stock option (right to buy)	06/09/2025	07/02/2034	Ordinary Shares	132,600(10)	$4.64	D
Stock option (right to buy)	08/12/2025	06/25/2035	Ordinary Shares	120,000(11)	$2.67	D
Stock option (right to buy)	06/09/2025	06/25/2035	Ordinary Shares	80,000(12)	$2.67	D

Explanation of Responses:

1. The options were granted on April 5, 2016 and fully vested as of April 5, 2019.

2. The options were granted on August 24, 2016 and fully vested as of August 24, 2019.

3. The options were granted on December 21, 2016 and fully vested as of December 21, 2019.

4. The options were granted on May 5, 2023 and vest on a quarterly basis until May 5, 2027.

5. The options were granted on June 11, 2020 and fully vested as of July 1, 2022.

6. The options were granted on August 9, 2021 and vest on a quarterly basis beginning August 9, 2022 until August 9, 2025.

7. The options were granted on May 3, 2022 and fully vested as of April 1, 2025.

8. The options were granted on October 9, 2023 and vest on a quarterly basis beginning August 7, 2024 until August 7, 2027.

9. The options were granted on July 2, 2024 and vest on a quarterly basis until May 6, 2028.

10. The options were granted on July 2, 2024 and vest on a quarterly basis until May 6, 2026.

11. The options were granted on June 25, 2025 and vest on a quarterly basis until May 12, 2029.

12. The options were granted on June 25, 2025 and vest on a quarterly basis until May 12, 2027.

	/s/ Dikla Czaczkes Akselbrad	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the PolyPid (PYPD) Form 3 filing by the CEO show?

The Form 3 shows CEO Dikla Czaczkes Akselbrad’s existing equity holdings in PolyPid. It lists directly owned Ordinary Shares and multiple stock options with specified exercise prices, vesting schedules, and expiration dates, providing a snapshot of her current compensation-linked exposure.

How many PolyPid (PYPD) Ordinary Shares does the CEO hold directly?

The CEO directly holds 934 Ordinary Shares of PolyPid. In addition to these shares, she has several stock option grants tied to Ordinary Shares, each with its own exercise price, vesting schedule, and expiration date, reflecting her broader economic stake.

What types of stock options are reported for the PolyPid (PYPD) CEO?

The filing lists multiple stock options (rights to buy) Ordinary Shares with exercise prices of 92.8900, 117.9900, 23.0700, 11.0100, 4.6400, and 2.6700. These options form part of her compensation and can be exercised before their respective expiration dates.

Do the PolyPid (PYPD) CEO’s options in this Form 3 represent new purchases or sales?

No, the entries are categorized as holdings rather than new transactions. The Form 3 simply reports existing direct ownership of Ordinary Shares and outstanding stock options, without recording any new market purchases, sales, exercises, or other changes in position.

When do the PolyPid (PYPD) CEO’s reported stock options expire?

The reported stock options have expiration dates ranging from 2026 through 2035. For example, some grants expire in 2026, while later awards with lower exercise prices run out as far as 2035-06-25, defining how long they can be exercised.

How do the vesting terms of the PolyPid (PYPD) CEO’s options differ?

Some option grants are disclosed as fully vested by specific past dates, while others vest on a quarterly basis over future periods extending to 2029. This mix shows both already-usable awards and compensation that continues to vest over time.